David T. Rubin, MD, on Biosimilars for Inflammatory Bowel Disease

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, on Cutting Cancer Care Costs With Alternative Pharmacologic Options

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, of Emory University, discusses the ways in which clinical pharmacology can help yield cost savings without sacrificing efficacy by, for example, altering regimens to extend drug supplies, lowering doses, dosing less frequently, or shortening the duration of treatment.

Dec

Today In Oncology

David T. Rubin, MD, on Biosimilars for Inflammatory Bowel Disease

Related Videos

Clifford A. Hudis, MD: Are Cancer Drug Prices in the U.S. the Problem or the Symptom?

Mark J. Ratain, MD: The Justification for a Randomized Trial of Low-Dose Ibrutinib

Opportunities to Optimize Cancer Policies Panel Discussion

Clinical Trial Design: Statistical Options/Challenges Panel Discussion

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, on Cutting Cancer Care Costs With Alternative Pharmacologic Options

Study Finds Daratumumab Monotherapy Prevented or Delayed Progression From Smoldering to Active Multiple Myeloma

Study Finds Genetic Changes, Elevated Leukemia Risk in Ground Zero First Responders

MRI First Strategy May Be Safe for Prostate Cancer Detection

Addition of SBRT to Systemic Therapy May Improve Outcomes in Select Patients With Locally Advanced Hepatocellular Carcinoma

Epcoritamab Monotherapy for Pretreated Relapsed or Refractory CLL